<?xml version="1.0" ?>
<document id="643ce1300f0c4056a709e1b13269a51924960a3a">
  <chunk id="643ce1300f0c4056a709e1b13269a51924960a3a.c0" text="Combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection">
    <entity charOffset="23-32" id="643ce1300f0c4056a709e1b13269a51924960a3a.c0.e0" ontology_id="CHEBI_63580" text="ribavirin" type="chemical"/>
    <entity charOffset="70-86" id="643ce1300f0c4056a709e1b13269a51924960a3a.c0.e1" ontology_id="DOID_1588" text="thrombocytopenia" type="disease"/>
    <entity charOffset="87-95" id="643ce1300f0c4056a709e1b13269a51924960a3a.c0.e2" ontology_id="DOID_225" text="syndrome" type="disease"/>
    <entity charOffset="96-111" id="643ce1300f0c4056a709e1b13269a51924960a3a.c0.e3" ontology_id="DOID_934" text="virus infection" type="disease"/>
    <pair e1="643ce1300f0c4056a709e1b13269a51924960a3a.c0.e0" e2="643ce1300f0c4056a709e1b13269a51924960a3a.c0.e1" id="643ce1300f0c4056a709e1b13269a51924960a3a.c0.p0" relation="true"/>
    <pair e1="643ce1300f0c4056a709e1b13269a51924960a3a.c0.e0" e2="643ce1300f0c4056a709e1b13269a51924960a3a.c0.e2" id="643ce1300f0c4056a709e1b13269a51924960a3a.c0.p1" relation="true"/>
    <pair e1="643ce1300f0c4056a709e1b13269a51924960a3a.c0.e0" e2="643ce1300f0c4056a709e1b13269a51924960a3a.c0.e3" id="643ce1300f0c4056a709e1b13269a51924960a3a.c0.p2" relation="true"/>
  </chunk>
  <chunk id="643ce1300f0c4056a709e1b13269a51924960a3a.c1" text="Background: Severe fever with thrombocytopenia syndrome (SFTS) is an acute infectious disease caused by SFTS virus and characterized by a high case fatality rate. Currently, there is no effective therapy for the disease. While the administration of ribavirin does not improve the case fatality rate or viral load in patient blood, it can inhibit viral infection in vitro.">
    <entity charOffset="30-46" id="643ce1300f0c4056a709e1b13269a51924960a3a.c1.e0" ontology_id="DOID_1588" text="thrombocytopenia" type="disease"/>
    <entity charOffset="47-55" id="643ce1300f0c4056a709e1b13269a51924960a3a.c1.e1" ontology_id="DOID_225" text="syndrome" type="disease"/>
    <entity charOffset="75-93" id="643ce1300f0c4056a709e1b13269a51924960a3a.c1.e2" ontology_id="DOID_0050117" text="infectious disease" type="disease"/>
    <entity charOffset="86-93" id="643ce1300f0c4056a709e1b13269a51924960a3a.c1.e3" ontology_id="DOID_4" text="disease" type="disease"/>
    <entity charOffset="212-219" id="643ce1300f0c4056a709e1b13269a51924960a3a.c1.e4" ontology_id="DOID_4" text="disease" type="disease"/>
    <entity charOffset="249-258" id="643ce1300f0c4056a709e1b13269a51924960a3a.c1.e5" ontology_id="CHEBI_63580" text="ribavirin" type="chemical"/>
    <entity charOffset="346-361" id="643ce1300f0c4056a709e1b13269a51924960a3a.c1.e6" ontology_id="DOID_934" text="viral infection" type="disease"/>
    <pair e1="643ce1300f0c4056a709e1b13269a51924960a3a.c1.e0" e2="643ce1300f0c4056a709e1b13269a51924960a3a.c1.e5" id="643ce1300f0c4056a709e1b13269a51924960a3a.c1.p0" relation="true"/>
    <pair e1="643ce1300f0c4056a709e1b13269a51924960a3a.c1.e1" e2="643ce1300f0c4056a709e1b13269a51924960a3a.c1.e5" id="643ce1300f0c4056a709e1b13269a51924960a3a.c1.p1" relation="true"/>
    <pair e1="643ce1300f0c4056a709e1b13269a51924960a3a.c1.e2" e2="643ce1300f0c4056a709e1b13269a51924960a3a.c1.e5" id="643ce1300f0c4056a709e1b13269a51924960a3a.c1.p2" relation="true"/>
    <pair e1="643ce1300f0c4056a709e1b13269a51924960a3a.c1.e3" e2="643ce1300f0c4056a709e1b13269a51924960a3a.c1.e5" id="643ce1300f0c4056a709e1b13269a51924960a3a.c1.p3" relation="true"/>
    <pair e1="643ce1300f0c4056a709e1b13269a51924960a3a.c1.e4" e2="643ce1300f0c4056a709e1b13269a51924960a3a.c1.e5" id="643ce1300f0c4056a709e1b13269a51924960a3a.c1.p4" relation="true"/>
    <pair e1="643ce1300f0c4056a709e1b13269a51924960a3a.c1.e5" e2="643ce1300f0c4056a709e1b13269a51924960a3a.c1.e6" id="643ce1300f0c4056a709e1b13269a51924960a3a.c1.p5" relation="true"/>
  </chunk>
  <chunk id="643ce1300f0c4056a709e1b13269a51924960a3a.c2" text="Methods: Vero cells were pre-treated with interferons (IFNs) α, β, and γ alone and in combination with ribavirin drugs and inoculated with SFTS virus. Three days later, supernatants were harvested and subjected to virus titration. An unpaired t-test was used for statistical analysis of the drugs' effects.">
    <entity charOffset="103-112" id="643ce1300f0c4056a709e1b13269a51924960a3a.c2.e0" ontology_id="CHEBI_63580" text="ribavirin" type="chemical"/>
    <entity charOffset="113-118" id="643ce1300f0c4056a709e1b13269a51924960a3a.c2.e1" ontology_id="CHEBI_23888" text="drugs" type="chemical"/>
    <entity charOffset="291-296" id="643ce1300f0c4056a709e1b13269a51924960a3a.c2.e2" ontology_id="CHEBI_23888" text="drugs" type="chemical"/>
  </chunk>
  <chunk id="643ce1300f0c4056a709e1b13269a51924960a3a.c3" text="Results: While the effects of IFNγ at high concentrations were slightly weaker than those of the other IFNs, all IFNs showed dose-dependent inhibitory effects. The combined usage of IFNs with ribavirin at 90 % effective concentrations showed large inhibitory effects, with over a 3 log 10 reduction in viral titers.">
    <entity charOffset="192-201" id="643ce1300f0c4056a709e1b13269a51924960a3a.c3.e0" ontology_id="CHEBI_63580" text="ribavirin" type="chemical"/>
  </chunk>
  <chunk id="643ce1300f0c4056a709e1b13269a51924960a3a.c4" text="The combined usage of one of type-I/II IFNs with ribavirin drastically reduced SFTS virus infection and therefore may be useful in the treatment of SFTS.">
    <entity charOffset="49-58" id="643ce1300f0c4056a709e1b13269a51924960a3a.c4.e0" ontology_id="CHEBI_63580" text="ribavirin" type="chemical"/>
    <entity charOffset="84-99" id="643ce1300f0c4056a709e1b13269a51924960a3a.c4.e1" ontology_id="DOID_934" text="virus infection" type="disease"/>
    <pair e1="643ce1300f0c4056a709e1b13269a51924960a3a.c4.e0" e2="643ce1300f0c4056a709e1b13269a51924960a3a.c4.e1" id="643ce1300f0c4056a709e1b13269a51924960a3a.c4.p0" relation="true"/>
  </chunk>
</document>
